Dad’s Leukaemia Fundraising Efforts Shift Focus to China

A dad who raised an impressive €600k for leukaemia treatment is now switching his focus to China, where a promising new treatment is being developed. CNCT19, an investigational CAR-T cell therapy, has shown significant clinical benefits in treating relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) in adults. The China National Medical Products Administration (NMPA) has accepted Juventas Cell Therapy’s new drug application (NDA) for CNCT19, marking a crucial milestone in making this treatment available to patients in China and potentially worldwide.